There’s A New Battery King And It’s Minting Billionaires Faster Than Google

TipRanks

2 Biotech Stocks With Big FDA Decisions in August

The biotech sector is famously volatile. Medical and pharmaceutical research involved both high overheads and years-long lead times, a combination that requires investors to be patient and to count on time frames that can sometimes reach a decade or more. But once a biotech gets a new medication onto the market, meeting a need for a substantial patient base, it’s all win – a combination of finding the Holy Grail and hitting the Powerball. It doesn’t always happen that way, however – so investors